BridgeMD
Compares treatment options for Left Ventricular Thrombus
Official title Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
ClinicalTrials.gov ID: NCT06515730
What this study is testing
What is Apixaban?
Apixaban is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for left ventricular thrombus.
Also referred to as Eliquis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years at the time of signing the informed consent
- LV thrombus confirmed on TTE\ day 1-28 after the AMI
- Signed informed consent
- Criteria applicable only for female people: Women of childbearing potential must provide a negative pregnancy test not be breastfeeding and be...
You likely can't join if
- Ongoing\ treatment with anticoagulant therapy due to Mechanical heart valve prosthesis Atrial fibrillation with or without significant mitral valve...
- High bleeding risk Active non-trivial bleeding Known chronic bleeding disorder Severe anemia defined as hemoglobin \< 80g/L Thrombocytopenia defined...
- Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or known hepatic insufficiency classified as Child-Pugh C...
- Known allergy, intolerance or hypersensitivity to either of the study interventions
- Any contraindication for the use of an anticoagulant or listed in the local labelling for apixaban or warfarin.
- Participation in other study investigating effects and safety of anticoagulant treatment.
See the full eligibility criteria
- Age ≥ 18 years at the time of signing the informed consent
- LV thrombus confirmed on TTE\ day 1-28 after the AMI
- Signed informed consent
- Criteria applicable only for female people: Women of childbearing potential must provide a negative pregnancy test not be breastfeeding and be willing and able to use highly effective contraception. Women of...
- Ongoing\ treatment with anticoagulant therapy due to Mechanical heart valve prosthesis Atrial fibrillation with or without significant mitral valve stenosis Venous thromboembolism requiring anticoagulant therapy...
- High bleeding risk Active non-trivial bleeding Known chronic bleeding disorder Severe anemia defined as hemoglobin \< 80g/L Thrombocytopenia defined as platelet count \< 80 x 10\^9
- Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or known hepatic insufficiency classified as Child-Pugh C or D at randomization
- Known allergy, intolerance or hypersensitivity to either of the study interventions
- Any contraindication for the use of an anticoagulant or listed in the local labelling for apixaban or warfarin.
- Participation in other study investigating effects and safety of anticoagulant treatment.
- Known current alcohol or drug abuse
- Any other condition, as judged by the investigator, that would make the participant unsafe or unsuitable for the study or life expectancy \< 6 months
The study team makes the final eligibility decision.
Where it's taking place
- Falun, Sweden
- Gothenburg, Sweden
- Linköping, Sweden
- Lund, Sweden
- Malmö, Sweden
- Nörrköping, Sweden
- Örebro, Sweden
- Stockholm, Sweden
- Uppsala, Sweden
- Västerås, Sweden
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Falun, Sweden; Gothenburg, Sweden; Linköping, Sweden; Lund, Sweden; Malmö, Sweden; Nörrköping, Sweden and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.